Cancer epidemiology · 2025
Prevalence of vaccine-induced immunity to hepatitis B in cancer patients: A 13-year analysis in a quaternary oncological center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Magri Mariana Cavalheiro, de Paula Victória Gonçalves, Pinto Marina Rossi de Camargo, Battaglia Débora Bignotto Rosane, de Oliveira Rafael, Ferreira Gustavo Manoel, Tengan Fátima Mitiko, Abdala Edson
Аннотация
BACKGROUND: Hepatitis B virus reactivation may occur in cancer patients, leading to liver damage and early discontinuation of treatment. To evaluate vaccine-induced immunity to hepatitis B, this study investigated the prevalence of anti-HBs antibodies from patients with solid tumors or hematological malignancies.
METHODS: All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10-99 IU/L) were evaluated by using multivariable logistic regression.
RESULTS: A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p < 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55-7.98), female sex (OR=1.25, 95 % CI: 1.15-1.36), non-white patients (OR=1.13, 95 % CI: 1.04-1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07-1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39-1.94) and female sex (OR=1.39, 95 % CI: 1.20-1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).
CONCLUSIONS: This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.
METHODS: All cancer patients who underwent serological testing for anti-HBs from 2011 to 2023 and had negative anti-HBc results at the Instituto do Cancer do Estado de Sao Paulo, Brazil, were included. The prevalence of vaccine-induced immunity to hepatitis B during those years was assessed by using linear regression. Characteristics associated with presence of anti-HBs and anti-HBs titers (strongly positive: ≥ 100 IU/L; weakly positive: 10-99 IU/L) were evaluated by using multivariable logistic regression.
RESULTS: A total of 23,854 patients were evaluated, 17,249 with solid tumors and 5114 with hematological malignancies. The prevalence of vaccine-induced immunity to hepatitis B was 22.1 %, with a significant linear increase over time (p < 0.001). The presence of vaccine-induced immunity to hepatitis B was associated with younger age (OR=7.23, 95 % CI: 6.55-7.98), female sex (OR=1.25, 95 % CI: 1.15-1.36), non-white patients (OR=1.13, 95 % CI: 1.04-1.22), and patients with hematological malignancies (OR=1.16, 95 %CI: 1.07-1.27). Additionally, the variables younger age (OR=1.64, 95 % CI: 1.39-1.94) and female sex (OR=1.39, 95 % CI: 1.20-1.60) were associated with strongly protective anti-HBs titers (≥ 100 IU/L).
CONCLUSIONS: This finding indicates that approximately one-quarter of a large population with cancer was protected against HBV infection through serological evidence of anti-HBs. Preventive strategies are needed for cancer patients, who may benefit from hepatitis B vaccination.